Prophylactic Human Vaccine Sales

Prophylactic Human Vaccine Sales Market Outlook

The global prophylactic human vaccine market is projected to reach approximately USD 65 billion by 2035, growing at a CAGR of around 8% during the forecast period from 2025 to 2035. This significant growth is primarily driven by the increasing incidences of infectious diseases, rising awareness regarding immunization, and advancements in vaccine development technology. Additionally, the growing emphasis on preventive healthcare and the heightened focus on global health security in the wake of pandemics like COVID-19 have resulted in increased funding for vaccine research and development. Governments and health organizations worldwide are investing in the improvement of vaccination programs, enhancing accessibility and affordability of vaccines for diverse populations. Furthermore, technological advancements and innovations in vaccine platforms, such as mRNA technology, are expected to revolutionize vaccine production and efficacy.

Growth Factor of the Market

The growth of the prophylactic human vaccine market can be attributed to several factors that are shaping the global healthcare landscape. First and foremost, the rise in vaccine-preventable diseases due to increasing population density and international travel has heightened the necessity for effective vaccination strategies. Additionally, the ongoing advancements in biotechnology and genomics are enabling the development of more effective and safer vaccines, thus boosting consumer confidence in vaccination programs. Furthermore, the support from governmental and non-governmental organizations in the form of funding and awareness campaigns has significantly increased vaccination uptake globally. The emergence of new infectious pathogens and the re-emergence of previously controlled diseases due to vaccine hesitancy are compelling healthcare authorities to prioritize vaccination as a crucial public health strategy. Lastly, the growing trend of personalized medicine and targeted therapies is also driving innovations in vaccine formulation and delivery mechanisms, thereby enhancing market growth.

Key Highlights of the Market

• Projected market size of USD 65 billion by 2035 with a CAGR of 8% from 2025 to 2035.
• Increasing focus on immunization and preventive healthcare globally.
• Technological advancements enabling the development of innovative vaccine platforms.
• Rising incidences of infectious diseases and novel pathogens driving vaccine demand.
• Robust investments and support from public and private sectors in vaccine research and development.

By Product Type

Live Attenuated Vaccines:

Live attenuated vaccines are crafted from live microorganisms that have been weakened or attenuated so that they cannot cause disease in healthy individuals. These vaccines elicit robust immune responses that often require fewer doses than other types of vaccines. The market for live attenuated vaccines is witnessing significant growth due to their proven effectiveness in preventing infectious diseases such as measles, mumps, and rubella. Additionally, the adaptability of these vaccines to be combined with other vaccines into single administration options is increasing their popularity. This segment's growth is further supported by global immunization initiatives aimed at eradicating diseases and enhancing herd immunity.

Inactivated Vaccines:

Inactivated vaccines are produced by killing the disease-causing microorganisms, ensuring they cannot cause disease while still eliciting an immune response. This type of vaccine is widely used for diseases like polio and hepatitis A. The inactivated vaccines market is projected to expand due to their safety profile, as they cannot revert to virulence. Furthermore, favorable regulatory approvals and advancements in inactivation techniques are enabling more efficient vaccine production. Healthcare professionals often recommend inactivated vaccines for specific populations, including those with immunocompromised conditions, thereby driving demand across diverse demographics.

Subunit Vaccines:

Subunit vaccines consist of purified pieces of the pathogen, such as proteins or sugars, which are capable of eliciting an immune response without introducing the whole germ into the body. This approach minimizes adverse effects while ensuring efficacy. The subunit vaccines segment is gaining traction, particularly in the context of modern vaccine development, due to their targeted immunogenic properties. They are widely used for diseases like human papillomavirus (HPV) and hepatitis B. This segment's growth is supported by increasing research and development into novel antigens and adjuvants, enhancing the immunogenicity of these vaccines.

Conjugate Vaccines:

Conjugate vaccines link a weak antigen with a strong immunogenic carrier, improving the immune response in young children, who may not respond well to polysaccharide antigens alone. This technology has been pivotal in preventing bacterial infections like Streptococcus pneumoniae and Neisseria meningitidis. The conjugate vaccines segment is expected to grow due to their ability to provide long-lasting immunity and the rising incidence of bacterial infections globally. Additionally, advancements in conjugate vaccine technology are enabling the development of broader-spectrum vaccines that can combat multiple strains of pathogens, further bolstering market growth.

DNA Vaccines:

DNA vaccines represent a novel approach to immunization, utilizing genetically engineered DNA to induce an immune response against specific pathogens. This innovative technology offers advantages such as stability, ease of production, and the potential for rapid development in response to emerging infectious diseases. The DNA vaccines segment is gaining momentum due to their efficacy in preclinical studies and ongoing clinical trials, particularly for diseases such as Zika and West Nile virus. The potential of DNA vaccines to be used for therapeutic applications, including cancer immunotherapy, positions them as a significant player in the future of vaccine development, contributing to their anticipated market growth.

By Application

Infectious Diseases:

The application of vaccines to prevent infectious diseases remains the most significant segment in the prophylactic human vaccine market. Vaccines for diseases such as measles, mumps, rubella, and influenza are critical in public health strategies aimed at disease elimination and control. The ongoing emergence of new infectious diseases, coupled with the resurgence of previously controlled diseases, is driving demand in this segment. Vaccination campaigns, especially in developing regions, are essential to reduce the incidence of infectious diseases and improve overall health outcomes. The global focus on achieving herd immunity through widespread vaccination programs continues to propel this segment's growth.

Cancer:

The use of prophylactic vaccines in cancer prevention is an emerging area that is gaining recognition in the healthcare sector. Vaccines targeting oncogenic viruses, such as the HPV vaccine for cervical cancer prevention, are pivotal in reducing the incidence of certain types of cancer. The market for cancer vaccines is expected to grow as awareness increases regarding the link between viral infections and cancer development. Furthermore, advancements in vaccine technology aimed at enhancing the efficacy of these vaccines are driving research and development efforts. The potential for integrating cancer vaccination into routine healthcare practices is also likely to contribute to market expansion.

Allergy:

Prophylactic vaccines aimed at reducing the incidence of allergic reactions are gaining traction as healthcare providers recognize the increasing prevalence of allergic diseases. These vaccines work by desensitizing individuals to specific allergens, thereby reducing the severity of allergic responses. The allergy application segment is projected to grow as more individuals seek effective treatment options. Additionally, the increasing burden of allergic diseases globally is prompting researchers to develop targeted vaccine therapies, leading to innovations that may significantly impact this market segment moving forward. Enhanced understanding of allergic mechanisms is also contributing to the development of more effective vaccines.

Other Non-Infectious Diseases:

Vaccination strategies are increasingly being explored for non-infectious diseases, driven by the recognition of the potential for preventive healthcare solutions in various medical fields. This category includes vaccines for diseases such as diabetes and cardiovascular conditions, where prevention strategies could significantly improve patient outcomes. As research continues to unveil the immunological underpinnings of these diseases, the market for vaccines targeting non-infectious diseases is likely to expand. This growing interest in non-infectious disease prevention reflects a broader shift toward holistic and preventive healthcare approaches, enhancing the overall market potential in this segment.

By Distribution Channel

Hospitals:

Hospitals play a critical role as a distribution channel for prophylactic human vaccines, providing direct access to immunization services for patients. Many hospitals have integrated vaccination programs within their outpatient services, ensuring that patients receive timely vaccinations during routine visits. The hospital distribution channel is expected to grow due to the increasing focus on preventive healthcare and the rising acceptance of vaccinations as a fundamental health strategy. Furthermore, hospitals often implement community outreach programs to educate the public about vaccination, further expanding their role in the distribution of vaccines.

Clinics:

Clinics, including family practice clinics and specialized health centers, are essential distribution points for vaccines, offering a range of immunization services. This channel is particularly important for pediatric vaccinations, as many families rely on clinics for their children's immunization schedules. The clinic segment is anticipated to grow as healthcare providers increasingly focus on preventive care and patient education. Additionally, the rise of urgent care clinics, which often provide vaccination services, is likely to enhance accessibility for patients. This growing number of clinic-based vaccination services is contributing to the overall expansion of the prophylactic human vaccine market.

Retail Pharmacies:

Retail pharmacies have emerged as a convenient access point for vaccinations, particularly for adult immunizations and seasonal flu shots. The integration of vaccination services within pharmacies has transformed the way patients receive vaccines, making them more accessible and convenient. As more individuals seek quick and efficient healthcare solutions, the retail pharmacy distribution channel is expected to expand significantly. Moreover, pharmacies often run promotional campaigns to encourage vaccination, which can further drive vaccine uptake within communities. The growing collaboration between pharmacies and healthcare providers is likely to enhance this segment’s market share.

Online Pharmacies:

Online pharmacies are increasingly becoming a viable distribution channel for vaccines, especially as telehealth and digital health solutions gain traction. While the distribution of physical vaccines remains a challenge, the ability to book appointments and receive consultations through online platforms is enhancing patient access to immunization services. The growth of this segment is also driven by the rising trend of e-commerce in healthcare, where patients can learn about vaccination options and find nearby locations for immunization. The online pharmacy segment represents a promising avenue for increasing vaccine accessibility and awareness, particularly in regions with limited healthcare infrastructure.

By Ingredient Type

Virus Particles:

Virus particles are integral components of many vaccines, particularly those designed to elicit a strong immune response against viral infections. Vaccines utilizing live attenuated or inactivated virus particles are crucial in combating diseases such as influenza and hepatitis. The segment is expected to grow as researchers continue to explore novel vaccine formulations that enhance the stability and efficacy of virus-based vaccines. The rising incidence of viral outbreaks globally is also propelling the demand for vaccines that utilize virus particles, thereby contributing to the expansion of this market segment.

Bacterial Toxins:

Bacterial toxins are utilized in the formulation of certain vaccines, specifically in preventing diseases caused by bacterial infections. Toxoid vaccines, which are derived from inactivated bacterial toxins, are essential for preventing diseases such as tetanus and diphtheria. The market for bacterial toxin-based vaccines is anticipated to grow due to the emphasis on immunization programs targeting bacterial infections. Additionally, advancements in toxin purification and formulation techniques are likely to enhance the safety and efficacy of these vaccines, further propelling market demand.

Recombinant Proteins:

Recombinant proteins serve as a key ingredient type in the development of subunit vaccines, which focus on specific antigens derived from pathogens. These proteins are engineered using recombinant DNA technology, allowing for the production of safe and effective vaccines. The recombinant protein segment is gaining traction, particularly as more vaccine candidates enter clinical trials and receive regulatory approval. The increasing understanding of immune responses and antigenic properties is facilitating the development of more targeted recombinant protein vaccines, which is expected to drive market growth significantly.

Nucleic Acids:

Nucleic acids, particularly in the form of mRNA vaccines, have revolutionized the prophylactic vaccine landscape. mRNA vaccines utilize synthetic messenger RNA to instruct cells to produce specific antigens, eliciting a robust immune response. This innovative technology gained significant attention during the COVID-19 pandemic and is now being explored for other infectious diseases and therapeutic applications. The nucleic acids segment is projected to grow as research continues to validate the efficacy and safety of this approach in broader applications. The flexibility and speed of mRNA vaccine development are key advantages that position nucleic acid-based vaccines for future growth in the market.

By Region

The North American prophylactic human vaccine market is anticipated to lead the global landscape due to a combination of advanced healthcare infrastructure, high vaccination rates, and robust R&D investment in vaccine development. The market is projected to reach approximately USD 30 billion by 2035, with a CAGR of around 7%. The established presence of major pharmaceutical companies and government initiatives to promote vaccination are also contributing to the region's growth. Moreover, the increasing public awareness surrounding vaccine-preventable diseases and the push for broader immunization coverage among diverse populations further enhance the market prospects in this region.

In Europe, the prophylactic human vaccine market is expected to show steady growth, with a projected market size of USD 20 billion by 2035, reflecting a CAGR of approximately 6%. The region benefits from well-established healthcare systems and comprehensive vaccination programs that facilitate high vaccine coverage rates. European countries are increasingly focusing on addressing vaccine hesitancy and ensuring equitable access to immunization services, which are essential for controlling infectious diseases. Additionally, the collaboration between public health authorities and pharmaceutical companies is driving innovation in vaccine development, which is crucial for responding to emerging health threats.

Opportunities

The prophylactic human vaccine market is poised for substantial opportunities driven by the ongoing advancements in biotechnology and increasing public awareness about the significance of immunization. The emergence of new technologies, such as mRNA vaccine platforms, offers the potential to expedite the development of vaccines for both infectious and non-infectious diseases. As healthcare systems across the globe continue to prioritize preventive measures, there is a growing demand for innovative vaccines that can address emerging health threats. Furthermore, partnerships and collaborations between pharmaceutical companies, research institutions, and governmental organizations are expected to foster a conducive environment for vaccine innovation and development, leading to a more comprehensive range of vaccine options for patients.

Moreover, the rising incidence of infectious diseases and the continuous threat of pandemics present significant opportunities for market expansion. The global focus on achieving herd immunity and the need for vaccination against emerging pathogens are likely to drive demand for new vaccine candidates. Additionally, the growing trend toward personalized medicine opens avenues for developing tailored vaccines that cater to specific populations and individual health conditions. Investment in educational campaigns aimed at reducing vaccine hesitancy and improving public perception of vaccination will also play a crucial role in enhancing vaccine uptake. Overall, the combination of technological advancements, growing public health initiatives, and increased awareness of vaccination benefits positions the prophylactic human vaccine market for remarkable growth in the coming years.

Threats

Despite the promising outlook for the prophylactic human vaccine market, several threats could potentially hinder its growth. One of the most significant challenges is vaccine hesitancy, which has been exacerbated by misinformation and anti-vaccine movements. Concerns regarding vaccine safety and efficacy can lead to reduced vaccination rates, undermining public health efforts aimed at controlling infectious diseases. Furthermore, geopolitical issues and vaccine nationalism can create disparities in vaccine distribution and accessibility, particularly in low- and middle-income countries. Such disparities can result in localized outbreaks of diseases that could have otherwise been controlled through widespread immunization.

Another concern is the potential for rapid mutations in pathogens, which may render existing vaccines less effective or inadequate. The emergence of vaccine-resistant strains of diseases, particularly in the face of global travel and trade, poses significant challenges for public health authorities. Additionally, regulatory hurdles and lengthy approval processes can delay the introduction of new vaccines to the market, limiting timely responses to emerging health threats. Lastly, competition among vaccine manufacturers and fluctuating market dynamics may lead to pricing pressures, affecting both innovation and accessibility. Addressing these threats effectively requires coordinated efforts from governments, healthcare organizations, and the pharmaceutical industry to ensure that vaccination remains a top priority in public health agendas.

Competitor Outlook

• Pfizer Inc.
• Moderna, Inc.
• Sanofi S.A.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Johnson & Johnson
• AstraZeneca plc
• Boehringer Ingelheim
• Novavax, Inc.
• Valneva SE
• AbbVie Inc.
• Serum Institute of India Pvt. Ltd.
• CanSino Biologics Inc.
• Sinovac Biotech Ltd.
• VBI Vaccines Inc.

The competitive landscape of the prophylactic human vaccine market is characterized by the presence of several key players that are actively engaged in research, development, and commercialization of vaccines. Major pharmaceutical companies are investing heavily in vaccine innovation, aiming to develop more effective and safer vaccination options to meet the growing demand for immunization. The competitive environment is dynamic, with companies continuously adapting to emerging health threats and changing market demands. Collaboration between industry players and public health organizations is becoming increasingly common, as stakeholders recognize the importance of collective efforts in addressing global vaccination challenges.

Pfizer Inc. is recognized for its significant contributions to the vaccine market with its widely acclaimed mRNA COVID-19 vaccine, which has set a new standard for vaccine development and deployment. The company continues to invest in research for next-generation vaccines targeting various infectious diseases and exploring combination vaccines that could simplify vaccination schedules. Similarly, Moderna, Inc. has established itself as a leader in mRNA vaccine technology, with ongoing projects aimed at developing vaccines for different infectious pathogens, including seasonal flu and RSV. Both companies showcase the potential of innovative platforms to revolutionize vaccine delivery and efficacy.

Sanofi S.A. and GlaxoSmithKline plc are also key players in the prophylactic human vaccine market, focusing on traditional vaccine production alongside novel approaches. Sanofi is investing in expanding its vaccine portfolio by developing vaccines for infectious diseases and exploring therapeutic vaccine candidates for cancer prevention. GlaxoSmithKline, known for its extensive range of vaccines, is pursuing advancements in vaccine formulations and delivery mechanisms to enhance immunogenicity and patient compliance. These companies are reaffirming their commitment to global health by participating in initiatives aimed at increasing vaccination coverage and combating vaccine-preventable diseases.

• 1 Appendix

  • 1.1 List of Tables
  • 1.2 List of Figures

• 2 Introduction

  • 2.1 Market Definition
  • 2.2 Scope of the Report
  • 2.3 Study Assumptions
  • 2.4 Base Currency & Forecast Periods

• 3 Market Dynamics

  • 3.1 Market Growth Factors
  • 3.2 Economic & Global Events
  • 3.3 Innovation Trends
  • 3.4 Supply Chain Analysis

• 4 Consumer Behavior

  • 4.1 Market Trends
  • 4.2 Pricing Analysis
  • 4.3 Buyer Insights

• 5 Key Player Profiles

  • 5.1 Valneva SE
    • 5.1.1 Business Overview
    • 5.1.2 Products & Services
    • 5.1.3 Financials
    • 5.1.4 Recent Developments
    • 5.1.5 SWOT Analysis
  • 5.2 AbbVie Inc.
    • 5.2.1 Business Overview
    • 5.2.2 Products & Services
    • 5.2.3 Financials
    • 5.2.4 Recent Developments
    • 5.2.5 SWOT Analysis
  • 5.3 Pfizer Inc.
    • 5.3.1 Business Overview
    • 5.3.2 Products & Services
    • 5.3.3 Financials
    • 5.3.4 Recent Developments
    • 5.3.5 SWOT Analysis
  • 5.4 Sanofi S.A.
    • 5.4.1 Business Overview
    • 5.4.2 Products & Services
    • 5.4.3 Financials
    • 5.4.4 Recent Developments
    • 5.4.5 SWOT Analysis
  • 5.5 Moderna, Inc.
    • 5.5.1 Business Overview
    • 5.5.2 Products & Services
    • 5.5.3 Financials
    • 5.5.4 Recent Developments
    • 5.5.5 SWOT Analysis
  • 5.6 Novavax, Inc.
    • 5.6.1 Business Overview
    • 5.6.2 Products & Services
    • 5.6.3 Financials
    • 5.6.4 Recent Developments
    • 5.6.5 SWOT Analysis
  • 5.7 AstraZeneca plc
    • 5.7.1 Business Overview
    • 5.7.2 Products & Services
    • 5.7.3 Financials
    • 5.7.4 Recent Developments
    • 5.7.5 SWOT Analysis
  • 5.8 Johnson & Johnson
    • 5.8.1 Business Overview
    • 5.8.2 Products & Services
    • 5.8.3 Financials
    • 5.8.4 Recent Developments
    • 5.8.5 SWOT Analysis
  • 5.9 Merck & Co., Inc.
    • 5.9.1 Business Overview
    • 5.9.2 Products & Services
    • 5.9.3 Financials
    • 5.9.4 Recent Developments
    • 5.9.5 SWOT Analysis
  • 5.10 VBI Vaccines Inc.
    • 5.10.1 Business Overview
    • 5.10.2 Products & Services
    • 5.10.3 Financials
    • 5.10.4 Recent Developments
    • 5.10.5 SWOT Analysis
  • 5.11 GlaxoSmithKline plc
    • 5.11.1 Business Overview
    • 5.11.2 Products & Services
    • 5.11.3 Financials
    • 5.11.4 Recent Developments
    • 5.11.5 SWOT Analysis
  • 5.12 Boehringer Ingelheim
    • 5.12.1 Business Overview
    • 5.12.2 Products & Services
    • 5.12.3 Financials
    • 5.12.4 Recent Developments
    • 5.12.5 SWOT Analysis
  • 5.13 Sinovac Biotech Ltd.
    • 5.13.1 Business Overview
    • 5.13.2 Products & Services
    • 5.13.3 Financials
    • 5.13.4 Recent Developments
    • 5.13.5 SWOT Analysis
  • 5.14 CanSino Biologics Inc.
    • 5.14.1 Business Overview
    • 5.14.2 Products & Services
    • 5.14.3 Financials
    • 5.14.4 Recent Developments
    • 5.14.5 SWOT Analysis
  • 5.15 Serum Institute of India Pvt. Ltd.
    • 5.15.1 Business Overview
    • 5.15.2 Products & Services
    • 5.15.3 Financials
    • 5.15.4 Recent Developments
    • 5.15.5 SWOT Analysis

• 6 Market Segmentation

  • 6.1 Prophylactic Human Vaccine Sales Market, By Application
    • 6.1.1 Infectious Diseases
    • 6.1.2 Cancer
    • 6.1.3 Allergy
    • 6.1.4 Other Non-Infectious Diseases
  • 6.2 Prophylactic Human Vaccine Sales Market, By Product Type
    • 6.2.1 Live Attenuated Vaccines
    • 6.2.2 Inactivated Vaccines
    • 6.2.3 Subunit Vaccines
    • 6.2.4 Conjugate Vaccines
    • 6.2.5 DNA Vaccines
  • 6.3 Prophylactic Human Vaccine Sales Market, By Ingredient Type
    • 6.3.1 Virus Particles
    • 6.3.2 Bacterial Toxins
    • 6.3.3 Recombinant Proteins
    • 6.3.4 Nucleic Acids
    • 6.3.5 Adjuvants
  • 6.4 Prophylactic Human Vaccine Sales Market, By Distribution Channel
    • 6.4.1 Hospitals
    • 6.4.2 Clinics
    • 6.4.3 Retail Pharmacies
    • 6.4.4 Online Pharmacies

• 7 Competitive Analysis

  • 7.1 Key Player Comparison
  • 7.2 Market Share Analysis
  • 7.3 Investment Trends
  • 7.4 SWOT Analysis

• 8 Research Methodology

  • 8.1 Analysis Design
  • 8.2 Research Phases
  • 8.3 Study Timeline

• 9 Future Market Outlook

  • 9.1 Growth Forecast
  • 9.2 Market Evolution

• 10 Geographical Overview

  • 10.1 Europe - Market Analysis
    • 10.1.1 By Country
      • 10.1.1.1 UK
      • 10.1.1.2 France
      • 10.1.1.3 Germany
      • 10.1.1.4 Spain
      • 10.1.1.5 Italy
  • 10.2 Asia Pacific - Market Analysis
    • 10.2.1 By Country
      • 10.2.1.1 India
      • 10.2.1.2 China
      • 10.2.1.3 Japan
      • 10.2.1.4 South Korea
  • 10.3 Latin America - Market Analysis
    • 10.3.1 By Country
      • 10.3.1.1 Brazil
      • 10.3.1.2 Argentina
      • 10.3.1.3 Mexico
  • 10.4 North America - Market Analysis
    • 10.4.1 By Country
      • 10.4.1.1 USA
      • 10.4.1.2 Canada
  • 10.5 Middle East & Africa - Market Analysis
    • 10.5.1 By Country
      • 10.5.1.1 Middle East
      • 10.5.1.2 Africa
  • 10.6 Prophylactic Human Vaccine Sales Market by Region

• 11 Global Economic Factors

  • 11.1 Inflation Impact
  • 11.2 Trade Policies

• 12 Technology & Innovation

  • 12.1 Emerging Technologies
  • 12.2 AI & Digital Trends
  • 12.3 Patent Research

• 13 Investment & Market Growth

  • 13.1 Funding Trends
  • 13.2 Future Market Projections

• 14 Market Overview & Key Insights

  • 14.1 Executive Summary
  • 14.2 Key Trends
  • 14.3 Market Challenges
  • 14.4 Regulatory Landscape

Segments Analyzed in the Report

The global Prophylactic Human Vaccine Sales market is categorized based on

By Product Type

• Live Attenuated Vaccines
• Inactivated Vaccines
• Subunit Vaccines
• Conjugate Vaccines
• DNA Vaccines

By Application

• Infectious Diseases
• Cancer
• Allergy
• Other Non-Infectious Diseases

By Distribution Channel

• Hospitals
• Clinics
• Retail Pharmacies
• Online Pharmacies

By Ingredient Type

• Virus Particles
• Bacterial Toxins
• Recombinant Proteins
• Nucleic Acids
• Adjuvants

By Region

• North America
• Europe
• Asia Pacific
• Latin America
• Middle East & Africa

Key Players

• Pfizer Inc.
• Moderna, Inc.
• Sanofi S.A.
• GlaxoSmithKline plc
• Merck & Co., Inc.
• Johnson & Johnson
• AstraZeneca plc
• Boehringer Ingelheim
• Novavax, Inc.
• Valneva SE
• AbbVie Inc.
• Serum Institute of India Pvt. Ltd.
• CanSino Biologics Inc.
• Sinovac Biotech Ltd.
• VBI Vaccines Inc.